New Website Launched for Those Suffering from Reglan Prescription Drug Injuries
25.02.10
New Website Launched for Those Suffering from Reglan Prescription Drug Injuries
Those suffering from tardive dyskinesia and other similar involuntary muscle movement conditions believed to have been the result of taking the prescription drug Reglan can now find information and support within the newly launched reglan-law-suit.com. The Reglan Information and Support Center website provides information regarding the prescription drug Reglan, its side effects, support resources, and legal information for those wanting to pursue litigation for injuries suffered from this prescription drug.
Houston, TX ( PRWEB ) February 25, 2010 -- There is now a new website dedicated to providing information and support to those suffering from health injuries related to taking the prescription drug Reglan. Reglan-law-suit.com, otherwise known as the Reglan Information and Support Center website provides useful information regarding the prescription drug Reglan and its potential harmful side effects, which include the involuntary muscle movement conditions known as tardive dyskinesia and dystonia tardive. These uncontrollable muscle movement conditions can cause a great deal of physical, mental, and emotional pain, and those suffering from these conditions can find support within raglan-law-suit.com.
Source: PR Web (press release)
Hospital Website says Reglan "safe" for Infants: that's news to us...
18.02.10
And have only minor side effects. If your child experiences side effects, we will adjust the dose or change medication.
No qualifying statements or footnotes. No references to use of Reglan in this capacity being off-label. No mentions of the info you’ll see on rxlist.com (run by webmd.com) for Reglan use in children, which reflects Reglan’s monograph:
Pediatric Use
Safety and effectiveness in pediatric patients have not been established (see OVERDOSAGE).
Care should be exercised in administering metoclopramide to neonates since prolonged clearance may produce excessive serum concentrations (see CLINICAL PHARMACOLOGY - Pharmacokinetics). In addition, neonates have reduced levels of NADH-cytochrome b5 reductase which, in combination with the aforementioned pharmacokinetic factors, make neonates more susceptible to methemoglobinemia (see OVERDOSAGE).
Source: Lawyers and Settlements (blog)